MTOR and cancer: Thus, potentially, modulation of the activity of NLRP1 and NLRP3, due to the effect of PUFA metabolites (majorly, 4-HNE, 8-isoprostanes, and PGE2) on mTOR signaling, appears as a prominent pharmacotherapeutic target, especially in the case of cancer therapies.